Important note: Information in this article was accurate in July 2005. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - Vol. 6, No. 7, July 2005
On 27 May 2005, FDA granted tentative approval to Ranbaxy Laboratories, for lamivudine tablets, 150 mg. This was followed a few week later, on 15 June, by tentative approval for generic lamivudine manufactured by Aurobindo Pharma.
On June 20, 2005, two applications for nevirapine (one from Ranbaxy, one from Aurobindo) also received tentative approval.
Four days later the FDA granted tentative approval for efavirenz tablets manufactured by Aurobindo Pharma. This product is the first tentatively approved generic version of efavirenz tablets.
Finally, on 1 July FDA granted tentative approval for d4T (stavudine) manufactured by Aurobindo Pharma.
A Tentative Approval means that FDA has concluded that a drug product has met all of the agency’s quality, safety and efficacy standards required for marketing in the US, even though it may not yet be marketed in the U.S. due to existing patents and/or exclusivity. It does, however, make the product eligible for use under the President’s Emergency Plan for AIDS Relief (PEPFAR) program outside the United States.
An archive of FDA list serve announcements is available on the FDA web site at:
Source: FDA list serve
050710
IB050607-10
©2005. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone / Firestone Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
